Global Blood Therapeutics Inc Stock Research

GBT Stock Price

GBT RSI Chart

GBT Valuation

Market Cap

4.6B

Price/Earnings (Trailing)

-14.29

Price/Sales (Trailing)

19.62

EV/EBITDA

-15.68

Price/Free Cashflow

-18.33

GBT Price/Sales (Trailing)

GBT Profitability

EBT Margin

-139.26%

Return on Equity

-272.44%

Return on Assets

-37.05%

Free Cashflow Yield

-5.46%

GBT Fundamentals

GBT Revenue

Revenue (TTM)

234.9M

Revenue Y/Y

50.46%

Revenue Q/Q

29.71%

GBT Earnings

Earnings (TTM)

-322.5M

Earnings Y/Y

-18.51%

Earnings Q/Q

-1.29%

Price Action

Last 7 days

0.5%

Last 30 days

1.0%

Last 90 days

104.5%

Trailing 12 Months

162.2%

GBT Financial Health

Current Ratio

6.88

Debt/Equity

2.94

Debt/Cashflow

-0.72

GBT Investor Care

Shares Dilution (1Y)

7.96%

Diluted EPS (TTM)

-5.01

Peers (Alternatives to Global Blood Therapeutics)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
BGNE	304.8B	1.4B	-3.73%	61.04%	-152.12	215.28	20.37%	-37.45%
ABBV	275.0B	58.1B	0.21%	1.63%	23.24	4.74	3.30%	2.55%
REGN	80.1B	12.2B	-0.48%	14.17%	18.47	6.58	-24.26%	-46.28%
VRTX	77.3B	8.9B	-1.64%	19.14%	23.26	8.65	17.91%	41.84%
ALNY	23.5B	1.0B	-16.46%	21.47%	-20.78	22.66	22.88%	-32.64%
SRPT	13.2B	933.0M	21.02%	90.98%	-18.71	14.11	32.93%	-67.99%
UTHR	10.1B	1.9B	-15.04%	21.63%	13.93	5.23	14.88%	52.86%
MID-CAP
MDGL	4.5B	504.0K	-6.48%	165.34%	-15.07	2.5K	-66.53%	-22.12%
RARE	2.8B	363.3M	-7.03%	-36.05%	-3.99	7.77	3.39%	-55.81%
BPMC	2.7B	204.0M	2.71%	-22.88%	-4.84	13.22	13.30%	13.44%
MRTX	2.5B	12.4M	-10.70%	-44.17%	-3.35	199.44	-	-27.34%
SMALL-CAP
CPRX	1.6B	191.8M	-7.72%	90.19%	24.49	8.55	43.59%	60.82%
MGNX	429.6M	93.0M	-0.16%	-22.78%	-2.25	4.62	-19.83%	-30.37%
CRBP	24.0M	-	-31.83%	665.59%	-0.57	19.11	-77.61%	7.22%
CYTK	3.5M	94.6M	-15.04%	9.81%	-0.01	0.04	34.30%	-80.65%

Financials for Global Blood Therapeutics

Income Statement (Last 12 Months)
Description	(%) Q/Q	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2
Revenue	11.4%	234,861,000	210,866,000	194,749,000	179,945,000	164,782,000
S&GA Expenses	7.1%	302,550,000	282,555,000	266,988,000	247,670,000	234,174,000
R&D Expenses	6.1%	227,102,000	214,111,000	212,135,000	194,238,000	183,905,000
EBITDA	-115.9%	-299,346,000	-138,664,000	-192,642,000	-	-
EBITDA Margin	-93.8%	-1.27	-0.66	-0.99	-	-
Earnings Before Taxes	-8.4%	-327,060,000	-301,628,000	-302,614,000	-288,738,000	-
EBT Margin	2.6%	-1.39	-1.43	-1.55	-	-
Interest Expenses	33.8%	21,661,000	16,188,000	13,938,000	11,377,000	9,652,000
Net Income	-4.2%	-322,462,000	-309,584,000	-303,091,000	-277,316,000	-266,209,000
Net Income Margin	6.5%	-1.37	-1.47	-1.56	-	-
Free Cahsflow	0.2%	-251,346,000	-251,765,000	-260,046,000	-	-

* denotes actual numbers (not divided by Millions)
Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2
Assets	0.1%	870	870	939	608	615
Current Assets	-5.3%	640	676	802	489	525
Cash Equivalents	-33.3%	261	392	685	383	419
Inventory	6.2%	66.00	62.00	58.00	52.00	48.00
Net PPE	-3.5%	32.00	34.00	35.00	35.00	37.00
Liabilities	2.2%	752	736	743	299	299
Current Liabilities	17.4%	93.00	79.00	88.00	74.00	73.00
Long Term Debt	-1.6%	348	353	359	192	195
LT Debt, Non Current	0.2%	247	247	246	150	149
Shareholder's Equity	-11.7%	118	134	196	308	316
Retained Earnings	-6.0%	-1,453	-1,370	-1,289	-1,201	-1,130
Additional Paid-In Capital	4.6%	1,576	1,507	1,486	1,510	1,446
Accumulated Depreciation	8.5%	18.00	17.00	16.00	14.00	13.00
Shares Outstanding	3.4%	67.00	65.00	65.00	64.00	62.00
Float	-	888	-	-	-	-

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2
Cashflow From Operations	0.0%	-249	-249	-256	-233	-209
Share Based Compensation	-1.8%	76.00	78.00	79.00	79.00	80.00
Cashflow From Investing	-63.9%	-390	-238	12.00	75.00	163
Cashflow From Financing	11.1%	482	434	434	123	80.00

Risks for GBT

What is the probability of a big loss on GBT?

100%

Probability that Global Blood Therapeutics stock will be more than 20% underwater in next one year

87.7%

Probability that Global Blood Therapeutics stock will be more than 30% underwater in next one year.

49.6%

Probability that Global Blood Therapeutics stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does GBT drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Global Blood Therapeutics was unfortunately bought at previous high price.

Drawdowns

Returns for GBT

Cumulative Returns on GBT

5.2%

7-Year Cumulative Returns

16.2%

5-Year Cumulative Returns

12.5%

3-Year Cumulative Returns

What are the long-term rolling returns for GBT?

FIve years rolling returns for Global Blood Therapeutics.

Annualized Returns

Which funds bought or sold GBT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-03-10	VICTORY CAPITAL MANAGEMENT INC	sold off	-100	-490,000	-	-%
2023-03-10	BAILLIE GIFFORD & CO	sold off	-100	-61,000	-	-%
2023-02-28	Voya Investment Management LLC	sold off	-100	-1,684,000	-	-%
2023-02-27	Parallax Volatility Advisers, L.P.	sold off	-100	-356,000	-	-%
2023-02-24	NATIXIS	sold off	-100	-12,026,000	-	-%
2023-02-21	MACQUARIE GROUP LTD	sold off	-100	-225,000	-	-%
2023-02-16	SkyView Investment Advisors, LLC	sold off	-100	-52,000	-	-%
2023-02-15	JANE STREET GROUP, LLC	sold off	-100	-4,353,000	-	-%
2023-02-15	Metropolitan Life Insurance Co/NY	sold off	-100	-267,000	-	-%
2023-02-15	PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO	sold off	-100	-4,086,000	-	-%

Latest Funds Activity

Are funds buying GBT calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own GBT

No. of Funds

Global Blood Therapeutics News

Schedule 13G FIlings of Global Blood Therapeutics

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2023	deep track capital, lp	0%	0	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Jun 17, 2022	deep track capital, lp	5.60%	3,646,690	SC 13G
Feb 14, 2022	point72 asset management, l.p.	0.3%	183,471	SC 13G/A
Feb 14, 2022	perceptive advisors llc	5.4%	3,449,915	SC 13G/A
Feb 14, 2022	baker bros. advisors lp	5.1%	3,314,765	SC 13G
Feb 14, 2022	price t rowe associates inc /md/	5.0%	3,260,685	SC 13G/A
Feb 09, 2022	fmr llc	-	0	SC 13G
Feb 03, 2022	blackrock inc.	8.3%	5,353,056	SC 13G/A
Jan 31, 2022	bank of america corp /de/	2.5%	1,603,685	SC 13G/A

GBT Fair Value

Recent SEC filings of Global Blood Therapeutics

View All Filings

Date Filed	Form Type	Document
Feb 14, 2023	SC 13G/A	Major Ownership Report
Feb 09, 2023	SC 13G/A	Major Ownership Report

Latest Insider Trading transactions for GBT

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2022-10-05	LOVE TED W	back to issuer	-	-	-119,650	president and ceo
2022-10-05	PIERCE GLENN	back to issuer	-	-	-26,437	-
2022-10-05	Morrison Scott W	back to issuer	-	-	-6,637	-
2022-10-05	Choi Jung	back to issuer	-	-	-226,672	see remarks
2022-10-05	PATRICK DEVAL L	back to issuer	-	-	-9,037	-
2022-10-05	Thompson Alexis A.	back to issuer	-	-	-3,308	-
2022-10-05	Smith-Whitley Kim	back to issuer	-	-	-5,980	see remarks
2022-10-05	Choi Jung	back to issuer	-	-	-25,000	see remarks
2022-10-05	JOHNSON DAVID LEE	back to issuer	-	-	-34,384	chief commercial officer
2022-10-05	SUVARI TRICIA BORGA	back to issuer	-	-	-43,077	chief legal officer

About Global Blood Therapeutics

Ted W. Love

www.globalbloodtx.com

460

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.

GBT Income Statement

2022-06-30

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenues [Abstract]
Product sales, net	$ 71,550	$ 47,555	$ 126,710	$ 86,598
Costs and operating expenses:
Cost of sales	1,413	748	2,468	1,332
Research and development	64,775	51,784	117,608	102,641
Selling, general and administrative	81,088	61,093	155,622	120,059
Total costs and operating expenses	147,276	113,625	275,698	224,032
Loss from operations	(75,726)	(66,070)	(148,988)	(137,434)
Other income (expense):
Interest income	1,664	164	2,164	493
Interest expense	(8,402)	(3,677)	(16,607)	(7,366)
Other income (expense), net	186	21	(100)	(62)
Total other income (expense,), net	(6,552)	(3,492)	(14,543)	(6,935)
Loss before income taxes	(82,278)	(69,562)	(163,531)	(144,369)
Provision for income taxes	192	30	362	153
Net loss	(82,470)	(69,592)	(163,893)	(144,522)
Other comprehensive loss:
Net unrealized gain on marketable securities, net of tax	(1,711)	(78)	(3,626)	(259)
Cumulative translation adjustment	(300)	259	(446)	259
Total other comprehensive expense, net	(2,011)	181	(4,072)	0
Comprehensive loss	$ (84,481)	$ (69,411)	$ (167,965)	$ (144,522)
Basic net loss per common share	$ (1.26)	$ (1.12)	$ (2.51)	$ (2.32)
Diluted net loss per common share	$ (1.26)	$ (1.12)	$ (2.51)	$ (2.32)
Weighted-average number of shares used in computing basic net loss per common share	65,594,792	62,312,418	65,220,518	62,207,328
Weighted-average number of shares used in computing diluted net loss per common share	65,594,792	62,312,418	65,220,518	62,207,328

GBT Balance Sheet

2022-06-30

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 261,152	$ 684,717
Short-term marketable securities	256,006	0
Accounts receivable, net	29,765	28,800
Inventories	65,816	58,202
Prepaid expenses and other current assets	27,272	30,251
Total current assets	640,011	801,970
Long-term marketable securities	146,863	50,057
Property and equipment, net	32,425	34,918
Operating lease right-of-use assets	46,497	48,015
Restricted cash	2,432	2,436
Other assets, noncurrent	2,214	1,812
Total assets	870,442	939,208
Current liabilities:
Accounts payable	8,260	15,097
Accrued liabilities	53,266	39,297
Accrued compensation	25,187	27,712
Other liabilities, current	6,379	5,892
Total current liabilities	93,092	87,998
Long-term debt, net	247,130	246,352
Convertible debt, net	334,815	334,089
Operating lease liabilities, noncurrent	70,322	73,506
Other liabilities, noncurrent	6,723	853
Total liabilities	752,082	742,798
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value, 5,000,000 shares authorized as of June 30, 2022 (unaudited) and December 31, 2021; no shares issued and outstanding	0	0
Common stock, $0.001 par value, 150,000,000 shares authorized as of June 30, 2022 (unaudited) and December 31, 2021, respectively; 67,257,761 and 64,636,641 shares issued and outstanding as of June 30, 2022 (unaudited) and December 31, 2021, respectively	67	65
Additional paid-in capital	1,575,719	1,485,805
Accumulated other comprehensive income	(3,973)	100
Accumulated deficit	(1,453,453)	(1,289,560)
Total stockholders' equity	118,360	196,410
Total liabilities and stockholders' equity	$ 870,442	$ 939,208